BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29095355)

  • 21. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up.
    Meyer LM; Schönfeld CL
    J Ocul Pharmacol Ther; 2013; 29(6):560-5. PubMed ID: 23480270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases.
    Rezkallah A; Mathis T; Denis P; Kodjikian L
    J Glaucoma; 2019 Jan; 28(1):e5-e9. PubMed ID: 30234749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Dexamethasone Intravitreal Implant on Retinal Nerve Fiber Layer in Patients Diagnosed with Branch Retinal Vein Occlusion.
    Ayar O; Alpay A; Koban Y; Akdemir MO; Yazgan S; Canturk Ugurbas S; Ugurbas SH
    Curr Eye Res; 2017 Sep; 42(9):1287-1292. PubMed ID: 28632411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population.
    Choi W; Bae HW; Choi EY; Kim M; Kim EW; Kim CY; Kim M; Seong GJ
    Br J Ophthalmol; 2020 Oct; 104(10):1423-1429. PubMed ID: 32071035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study.
    Singer MA; Capone A; Dugel PU; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
    BMC Ophthalmol; 2015 Apr; 15():33. PubMed ID: 25885285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis.
    Pelegrín L; de la Maza MS; Molins B; Ríos J; Adán A
    Eye (Lond); 2015 Jul; 29(7):943-50. PubMed ID: 25998942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined subconjunctival injection of dexamethasone for the management of acute primary angle closure: a randomised controlled trial.
    Huang W; Li X; Gao K; Zhang X
    Br J Ophthalmol; 2020 Jan; 104(1):87-91. PubMed ID: 31000508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EVALUATION OF MULTIPLE DEXAMETHASONE INTRAVITREAL IMPLANTS IN PATIENTS WITH MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION.
    Bakri SJ; Omar AF; Iezzi R; Kapoor KG
    Retina; 2016 Mar; 36(3):552-7. PubMed ID: 26418442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
    Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
    [No Abstract]   [Full Text] [Related]  

  • 30. SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension.
    Malclès A; Dot C; Voirin N; Vié AL; Agard É; Bellocq D; Denis P; Kodjikian L
    Retina; 2017 Jul; 37(7):1352-1359. PubMed ID: 27768641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraocular pressure after intravitreal injection of dexamethasone implant for macular edema resulting from retinal vein occlusion.
    Caillaux V; Valtot F; Souied EH; Mimoun G
    Eur J Ophthalmol; 2015; 25(5):454-8. PubMed ID: 25743778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children.
    Lei S; Lam WC
    Can J Ophthalmol; 2015 Jun; 50(3):236-41. PubMed ID: 26040225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexamethasone implant in pseudophakic and nonglaucomatous subgroup of diabetic macular edema patients: a real life experience.
    Ozkaya A; Alagoz C; Alagoz N; Gunes H; Yilmaz I; Perente I; Yazici AT; Taskapili M
    Eur J Ophthalmol; 2016 Jun; 26(4):351-5. PubMed ID: 26692061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EFFICACY AND SAFETY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR PERSISTENT UVEITIC CYSTOID MACULAR EDEMA.
    Khurana RN; Porco TC
    Retina; 2015 Aug; 35(8):1640-6. PubMed ID: 25741813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study.
    Chiquet C; Dupuy C; Bron AM; Aptel F; Straub M; Isaico R; Romanet JP; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2095-102. PubMed ID: 25673251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion.
    Yuksel B; Karti O; Celik O; Kerci SG; Kusbeci T
    Clin Exp Optom; 2018 Jan; 101(1):116-122. PubMed ID: 28922697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.
    Eter N; Mohr A; Wachtlin J; Feltgen N; Shirlaw A; Leaback R;
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):77-87. PubMed ID: 27460280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice.
    Hemarat K; Kemmer JD; Porco TC; Eaton AM; Khurana RN; Stewart JM
    Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):680-685. PubMed ID: 30222802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION.
    Sudhalkar A; Kodjikian L; Chhablani J; Bhojwani D; Vasavada A
    Retina; 2018 Dec; 38(12):2343-2349. PubMed ID: 29016454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema.
    Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Bacherini D; Guerriero S; Favale RA; Fusco F; Franceschini R; Frediani B; Iannone F; Galeazzi M; Tosi GM; Cantarini L
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):549-555. PubMed ID: 28557602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.